Danna nan idan wannan shine sakin labaran ku!

An Sanar da Sabon Nazarin Maganin Cutar Daji A Kasar China

Written by edita

Innovent Biologics, Inc. (Innovent), wani kamfani na biopharmaceutical na duniya wanda ke tasowa, kerawa da kuma sayar da magunguna masu inganci don maganin ciwon daji, metabolism, autoimmune da sauran manyan cututtuka, da NeoCura Bio-Medical Technology Co., Ltd. ( NeoCura), babban kamfanin AI-enabled RNA madaidaicin likitan ilimin halittu, wanda ya himmatu wajen gina babban dandalin fasahar fasahar RNA na duniya, a yau tare da sanar da cewa sun shiga yarjejeniyar hadin gwiwa bisa dabarun gudanar da wani binciken asibiti a kasar Sin kan hadewar sintilimab. daga Innovent da keɓaɓɓen rigakafin neoantigen NEO_PLIN2101 daga NeoCura.

Print Friendly, PDF & Email

Innovent za ta hada kai tare da NeoCura a kasar Sin don tantance aminci, pharmacokinetics, pharmacodynamics da kuma na farko inganci na hade far ta amfani da sintilimab daga Innovent da NEO_PLIN2101 daga NeoCura a cikin marasa lafiya da ciwon daji, don ci gaba da asibiti ci gaban hade immunotherapy ga mahara m ciwace-ciwacen daji da kuma shirya sallama. aikace-aikacen Sabbin Magunguna na Bincike (IND) zuwa Hukumar Kula da Kayayyakin Magunguna ta Kasa (NMPA) nan gaba kadan.

Dokta Liu Yongjun, shugaban Innovent, ya bayyana cewa: "Mun gamsu da bambancin bututun R&D na NeoCura da ƙungiyar bincike ta kasa da kasa, kuma muna farin cikin shiga cikin wannan haɗin gwiwar dabarun don gano darajar asibiti na sintilimab tare da allurar rigakafin neoantigen don ingantaccen ciwace-ciwace. . Innovent yana da bututu mai ƙarfi tare da ƙarfi mai ƙarfi a ilimin rigakafi da ilimin halittar kansa. A halin yanzu, muna da sabbin magunguna guda biyar da aka amince da su kuma aka kaddamar da su a kasar Sin, kuma za mu sami sabbin magunguna sama da 10 da za a harba a cikin shekaru 2-3 masu zuwa. Cikakken tsarin haɗin gwiwarmu ya tara R&D mai ƙarfi, haɓakar asibiti da damar kasuwanci kuma yana da kyau ga abokan haɗin gwiwa a gida da waje. Har ila yau, muna fatan za mu ci gaba da bincika sabbin damammaki na faɗaɗa alamomi da haɓaka ingantaccen magani na sintilimab tare da sabbin hanyoyin kwantar da hankali. Muna sa ran samun haɗin gwiwa mai zurfi da zurfi a tsakanin bangarorin biyu nan gaba. "

Dr. Wang Yi, wanda ya kafa NeoCura, ya ce: “A halin yanzu, alluran rigakafin neoantigen wani tsarin warkewa ne na juyin juya hali a duk duniya. NeoCura yana mai da hankali kan R&D na alluran rigakafin neoantigen tun lokacin da aka kafa shi, yana fatan shawo kan ƙalubalen da ke tattare da rigakafi a cikin maganin ciwace-ciwace ta hanyar amfani da sabbin fasahohi. Haɗin gwiwa tare da Innovent zai taka rawar daidaitawa na keɓaɓɓen allurar rigakafin neoantigen da magungunan rigakafi na monoclonal tare da haɗin gwiwa tare da bincika tasirin aikin haɗin gwiwa a cikin jiyya na ciwace-ciwacen ciwace-ciwacen ƙwayoyi, wanda ake tsammanin zai haɓaka ƙimar amsawar cutar kansa da kuma kawo sabbin damammaki. don tsarin haɗin gwiwar kansa.

Print Friendly, PDF & Email

Game da marubucin

edita

Babban edita shine Linda Hohnholz.

Leave a Comment